HealthcareServices

Genital Warts Market Report 2026: Strategic Insights and Revenue Outlook

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the genital warts market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Genital Warts Market?

The genital warts market has experienced robust expansion in recent years. It is projected to increase from $2.06 billion in 2025 to $2.17 billion in 2026, at a compound annual growth rate (CAGR) of 5.1%. The growth observed in the historic period can be attributed to the high prevalence of HPV infections, the availability of topical drugs, the early adoption of ablative procedures, sexual health awareness programs, and clinical treatment guidelines.

The genital warts market is anticipated to show substantial growth in the upcoming years. It is projected to expand to $2.65 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.1%. This expansion during the forecast period can be attributed to broader hpv vaccination coverage, the emergence of new topical agents, an increase in outpatient treatment options, early detection campaigns, and patients favoring non-invasive care. Key trends for this period include a growing acceptance of topical treatment methods, enhanced awareness of hpv-related infections, an increasing call for minimally invasive ablative treatments, the expansion of preventive hpv vaccination programs, and greater utilization of home-based treatment alternatives.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18374&type=smp

Which Drivers Are Supporting The Rise Of The Genital Warts Market?

The rising occurrence of sexually transmitted infections (STIs) is expected to fuel the expansion of the genital warts market. STIs are contagions primarily spread through various forms of sexual contact, such as vaginal, anal, and oral sex, originating from bacteria, viruses, or parasites. The increasing number of sexually transmitted infections is attributed to factors like heightened sexual activity, insufficient protective measures, and restricted availability of educational resources and health services. As a frequent STI, genital warts stem from particular human papillomavirus (HPV) strains and are transmitted via direct skin-to-skin contact during sexual encounters. Illustrating this trend, the Centers for Disease Control and Prevention, a US-based government public health agency, disclosed in September 2025 that over 2.2 million cases of chlamydia, gonorrhea, and syphilis were recorded in 2024. Consequently, the expanding prevalence of sexually transmitted infections (STIs) is a key factor propelling the growth of the genital warts market.

What Leading Segments Are Studied In The Genital Warts Market?

The genital warts market covered in this report is segmented –

1) By Drug Type: Imiquimod, Podophyllin, Podofilox, Trichloroacetic Acid

2) By Treatment: Chemical Treatment, Ablative Treatment, Preventive Treatment, Other Treatments

3) By Gender: Female, Male

4) By End Users: Hospitals, Clinics, Home Care Settings

Subsegments:

1) By Imiquimod: Imiquimod Cream 5%, Imiquimod Cream 3.75%

2) By Podophyllin: Podophyllin Resin 10%, Podophyllin Resin 25%

3) By Podofilox: Podofilox Gel 0.5%, Podofilox Solution 0.5%

4) By Trichloroacetic Acid: Trichloroacetic Acid 80-90%, Trichloroacetic Acid 50-70%

How Are Emerging Trends Affecting The Progression Of The Genital Warts Market?

Leading companies in the genital warts market are creating innovative treatment options, such as new dermatology drugs, to address the difficulties encountered by patients with the condition. Dermatology drugs denote recently developed pharmaceuticals or therapeutic agents specifically designed to treat various dermatologic ailments, including genital warts. For example, in March 2023, Verrica Pharmaceuticals Inc., a US-based dermatology pharmaceutical company, was granted New Chemical Entity (NCE) status for its drug candidate YCANTH. YCANTH is being developed to treat genital warts and has successfully completed phase 2 trials. With this FDA NCE status, the company now has at least five years of protection from generic competition.

Which Key Players Are Driving Competition In The Genital Warts Market?

Major companies operating in the genital warts market are Merck & Co. Inc, Teva Pharmaceutical Industries Ltd, Sun Pharmaceuticals, Perrigo Company plc, Glenmark Pharmaceutical Inc, Taro Pharmaceutical Industries Ltd, ANI Pharmaceuticals Inc, Verrica Pharmaceuticals Inc, CryoConcepts LP, CryoIQ Global AB, Cassiopea Inc, GlaxoSmithKline plc, Pfizer Inc, Bayer AG, Astellas Pharma Inc, Amgen Inc, Boehringer Ingelheim, Johnson & Johnson, Eli Lilly and Company, Novan Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/genital-warts-global-market-report

Which Region Currently Holds The Largest Share Of The Genital Warts Market?

North America was the largest region in the genital warts market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genital warts market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Genital Warts Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18374&type=smp

Browse Through More Reports Similar to the Global Genital Warts Market 2026, By The Business Research Company

Vaginal Sling Market Report 2026

https://www.thebusinessresearchcompany.com/report/vaginal-sling-global-market-report

Warts Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/warts-therapeutics-global-market-report

Genital Herpes Market Report 2026

https://www.thebusinessresearchcompany.com/report/genital-herpes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795